Global Pulmonary Alveolar Proteinosis Drug Market, By Disease Type (Autoimmune Pulmonary Alveolar Proteinosis (aPAP), Congenital, Secondary Pulmonary Alveolar Proteinosis (PAP)), Drug Type (Rituximab, Others), Treatment (Whole Lung Lavage, Lung Transplant, Plasmapheresis, GM-CSF Replacement Therapy, Others), Diagnosis (Blood tests, Bronchoscopy, Imaging tests, Pulmonary function tests, Biopsy, Others), Route of Administration (Oral, Inhalation, Others), End-Users (Hospital, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028